Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.6.3819

Serum Talin-1 is a Potential Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Egyptian Patients  

Youns, Mahmoud M. (Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University)
Abdel Wahab, Abdel Hady A. (Department of Cancer Biology, National Cancer institute, Cairo University)
Hassan, Zeinab A. (Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University)
Attia, Mohamed S. (Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.6, 2013 , pp. 3819-3823 More about this Journal
Abstract
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide. The outcome of HCC depends mainly on its early diagnosis. To date, the performance of traditional biomarkers is unsatisfactory. Talins were firstly identified as cytoplasmic protein partners of integrins but Talin-1 appears to play a crucial role in cancer formation and progression. Our study was conducted to assess the diagnostic value of serum Talin-1 (TLN1) compared to the most feasible traditional biomarker alpha-fetoprotein (AFP) for the diagnosis of HCC. Methods: TLN1 was detected using enzyme linked immunosorbent assay (ELISA) in serum samples from 120 Egyptian subjects including 40 with HCC, 40 with liver cirrhosis (LC) and 40 healthy controls (HC). Results: ROC curve analysis was used to create a predictive model for TLN1 relative to AFP in HCC diagnosis. Serum levels of TLN1 in hepatocellular carcinoma patients were significantly higher compared to the other groups (p<0.0001). The diagnostic accuracy of TLN1 was higher than that of AFP regarding sensitivity, specificity, positive predictive value and negative predictive value in diagnosis of HCC. Conclusions: The present study showed for the first time that Talin-1 (TLN1) is a potential diagnostic marker for HCC, with a higher sensitivity and specificity compared to the traditional biomarker AFP.
Keywords
Hepatocellular carcinoma; Talin-1; alpha-fetoprotein; liver cirrhosis; marker;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Abdel-Aziz F, Habib M, Mohamed MK, et al (2000). Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology, 32, 111-5.   DOI   ScienceOn
2 Altekruse S, McGlynn K Reichman M (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27,1485-91.   DOI   ScienceOn
3 Attallah AM, El-Far M, Abdel Malak C, et al (2011). Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clinica Chimica Acta, 412, 2310-5.   DOI   ScienceOn
4 Bessa S, Elwan N, Suliman G, El-Shourbagy S (2010). Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res, 41, 541-7.   DOI   ScienceOn
5 Bruix J and Sherman M (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208-36.   DOI   ScienceOn
6 Critchley DR, Talin In Kreis T, Vale R (1999). Guidebook to the extracellular matrix, anchor, and adhesion proteins. Oxford University Press, pp. 82-85, Oxford.
7 El-Serag HB (2004). Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 127, 27-34.   DOI   ScienceOn
8 El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.   DOI   ScienceOn
9 El-Zayadi AR, Badran HM, Barakat EM, et al (2005). Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol, 11, 5193-8.
10 Ferlay J, Bray F, Pisani P (2004). GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press; Lyon: 2004. IARC CancerBase No. 5. version 2.0.
11 Freedman L, Edwards B, Ries L (2006). Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the middle east cancer consortium (MECC) compared with US SEER. National Cancer Institute. Bethesda, MD: NIH Pub. No. 06-5873.
12 Hassan MM, Zaghloul AS, El-Serag HB (2001). The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol, 33, 123-6.   DOI   ScienceOn
13 Horwitz A, Duggan K, Buck C, et al (1986). Interaction of plasma-membrane fibronectin receptor with talin - a transmembrane linkage. Nature, 320, 531-3.   DOI   ScienceOn
14 Kanamori H, Kawakami T, Effendi K, et al (2011). Identification by differential tissue proteome analysis of Talin-1 as a novel molecular marker of progression of hepatocellular carcinoma. Oncology, 80, 406-15.   DOI   ScienceOn
15 Khattab MA, Eslam M, Sharwae MA (2010). Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008. Am J Infect Control, 38, 640-1.   DOI   ScienceOn
16 Liotta LA, Kohn E (2004). Anoikis: cancer and the homeless cell. Nature, 430, 973-4.   DOI   ScienceOn
17 Makuuchi M, Kokudo N, Arii S, et al (2008). Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res, 38, 37-51.   DOI   ScienceOn
18 Mendy M, Walton R (2009). Molecular pathogenesis and early detection of hepatocellular carcinoma-perspectives from West Africa. Cancer Lett, 286, 44-51.   DOI   ScienceOn
19 Mizejewski GJ (1999). Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med, 222, 124-38.   DOI   ScienceOn
20 Parkin D, Bray F, Ferlay J, Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6.   DOI   ScienceOn
21 Parkin D, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.   DOI   ScienceOn
22 Sakamoto S, McCann RO, Dhir R, Kyprianou N (2010). Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res, 70, 1885-95.   DOI
23 Senetar M, Moncman C, McCann R (2007). Talin2 is induced during striated muscle differentiation and istargeted to stable adhesion complexes in mature muscle. Cell Motil Cytoskeleton, 64, 157-73.   DOI   ScienceOn
24 Senetar MA, McCann RO (2005). Gene duplication and functional divergence during evolution of the cytoskeletal linker protein talin. Gene, 362, 141-52.   DOI   ScienceOn
25 Slater M, Cooper M, Murphy CR (2007). The cytoskeletal proteins alpha-actinin, Ezrin, and talin are De-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium. Appl Immunohistochem Mol Morphol, 15, 170-4.   DOI   ScienceOn
26 Tadokoro S, Shattil SJ, Eto K, et al (2003). Talin binding to integrin beta tails:a final common step in integrin activation. Science, 302, 103-6.   DOI   ScienceOn
27 Teofanescu I, Gologan E, Stefanescu E, Balan G (2010). Surveillance of cirrhosis for hepatocellular carcinoma--clinical validation of new serological biomarkers for improved diagnosis. Rev Med Chir Soc Med Nat Iasi, 114, 39-46.
28 Thomas M, Zhu A (2005). Hepatocellular carcinoma: the need for progress. J Clin Oncol, 23, 2892-9.   DOI   ScienceOn
29 Tsujioka M, Yoshida K, Inouye K (2004). Talin B is required for force transmission in morphogenesis of dictyostelium. EMBO J, 23, 2216-25.   DOI   ScienceOn
30 Zhang JL, Qian YB, Zhu LX, Xiong QR (2011). Talin1, a valuable marker for diagnosis and prognostic assessment of human hepatocelluar carcinomas. Asian Pac J Cancer Prev, 12, 3265-9.
31 Zhang X, Jiang G, Cai Y, et al (2008). Talin depletion reveals independence of initial cell spreading from integrin activation and traction. Nat Cell Biol, 10, 1062-8.   DOI   ScienceOn